Cure Parkinson’s is pleased to announce the first project from our iLCT Research Pipeline Acceleration Programme is now underway. Led by Professor Michael Schwarzchild, we hope this early-stage laboratory preclinical study will provide the evidence needed to determine if three iLCT-evaluated compounds are ready to progress into clinical trials for people with Parkinson’s.

Our International Linked Clinical Trials (iLCT) initiative involves a committee of the world’s leading Parkinson’s experts gathering annually to review and prioritise potentially disease-modifying drugs and compounds for clinical trials in Parkinson’s. Some that are not prioritised however, often show potential for Parkinson’s but lack key background information, like further biological evidence of efficacy in Parkinson’s, needed to justify progressing these compounds into clinical trials for people with Parkinson’s. The iLCT Research Pipeline Acceleration Programme aims to quickly provide this background evidence by commissioning research to fill the knowledge gaps.

We are excited to announce that the first project in our pipeline programme is now underway. Professor Michael Schwarzchild at Mass General Hospital in the US is leading an early stage preclinical study of three compounds: benfotiamine (a form of vitamin B1), methylcobalamin (a form of vitamin B12), and the anti-inflammatory drug, ibuprofen.

Professor Schwarzchild is testing whether these compounds are able to reduce the build-up of an abnormal toxic form of a protein called alpha-synuclein, to slow disease progression in laboratory models of Parkinson’s. Abnormal alpha-synuclein accumulates in the dopamine producing nerve cells or neurons of people with Parkinson’s and it is thought that this obstructs the neuron’s function, eventually leading to neuronal death. Preventing this process is of major interest to researchers looking for drugs that can slow or stop Parkinson’s progression.

The results of this study are expected in the second half of 2024 and we are pleased to have recently accepted further applications for our second grant call. To learn more about our iLCT Research Pipeline Acceleration Programme and how to apply, please visit our webpage below.

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?